Ritholtz Wealth Management lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 145.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 20,392 shares of the company’s stock after buying an additional 12,100 shares during the period. Ritholtz Wealth Management’s holdings in Zoetis were worth $1,424,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares in the last quarter. State Street Corp raised its position in Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after acquiring an additional 343,322 shares during the period. Deutsche Bank AG raised its position in Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after acquiring an additional 319,709 shares during the period. Bank of America Corp DE raised its position in Zoetis by 7.3% during the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after acquiring an additional 327,313 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Zoetis by 7.7% during the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock valued at $305,559,000 after purchasing an additional 303,395 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on ZTS. William Blair lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. BNP Paribas Exane reduced their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Jefferies Financial Group raised their price target on shares of Zoetis from $83.00 to $85.00 in a research note on Friday, November 6th. Finally, Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average price target of $101.25.
Read Our Latest Stock Report on ZTS
Zoetis Stock Performance
Shares of NYSE:ZTS opened at $83.65 on Monday. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. The business’s 50 day moving average price is $76.28 and its 200-day moving average price is $91.56. The firm has a market capitalization of $33.99 billion, a PE ratio of 14.23, a P/E/G ratio of 1.21 and a beta of 0.67. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the business earned $1.70 earnings per share. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is 36.05%.
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
